Skip to main content


Our Commitment

At BIORCHESTRA, we develop innovative medicines for patients and their families, offering hope to cure neglected and incurable diseases and improve the quality of life and health for all.


Premier biopharmaceutical company redefining what is possible in treating rare and neurodegenerative diseases through the impact of our therapeutic medicines


Our programs underpin our unwavering commitment to bring innovative medicines in service to patients, thereby addressing major unmet medical needs


Integrity, Teamwork, Innovation, Scientific Excellence, and Accountability​

Corporate Overview

Development Strategy

Target rare and degenerative CNS diseases (AD, ALS, Epilepsy, FTD, HD, PD, Familial PD)​

Lead Program

BMD-001: An IV formulated nanomedicine targeting a specific microRNA implicated across CNS diseases, with subsequent clearance of amyloid, reduction in tau protein deposition, decrease in neuroinflammation, and improvement in cognitive function


Broad portfolio of RNA interference chemistries – seven discovery and pre-clinical programs

Brain Targeting Drug Delivery System

Best-in-class technology enabling efficient encapsulation and targeted delivery of RNA therapeutics to brain cells

External Partnering Strategy

Multiple nondisclosed partnerships across a range of targets; additional licensing discussions ongoing

Innovative Therapeutics Programs